STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and more

Good morning and greetings from Pharmalot's New York bureau. Jason Mast is filling in today. He is still listening to the music recommendation from Pharmalot's Friday dispatch and trying to celebrate the coming autumn, rather than mourn the end of summer. Here are today's news updates:

The White House is expected to announce new drug pricing deals on Monday, according to the Financial Times. Bayer, Takeda, CSL Behring, and several mid-sized drugmakers are among the participating companies. The agreements represent the latest in a series of deals signed by the Trump administration with major drugmakers, typically involving drug pricing concessions in exchange for salary relief. However, it remains unclear how significant the drug pricing concessions actually are.

The FDA has approved Takeda and Protagonist's new drug, Mimrylo, for the treatment of slow-growing cancer, known as polycythemia vera. Mimrylo is a weekly injection that aims to combat the overproduction of red blood cells, which can lead to thickened blood and increase the risk of heart attacks, strokes, and blood clots. The companies have not disclosed the price of the drug. For more details, continue reading STAT+.